Insights

Holdsway meeting image

Transforming People, Process and Technology in Life Sciences

17th March 2026

When a global life science technology company needed to transform people, process and technology they called us.

Backed by private equity they faced critical operational failure during exit preparation, the business needed immediate, decisive leadership.

Holdsway hand-picked an experienced interim who had previously taken on roles as CIO, CTO  and Chief Digital & AI Officer from its extensive network to be Interim VP Solution Deployment and lead a rapid transformation of people, process and technology.

We met with the client, and the mandate became very clear:

  • Stabilise failing medical data services
  • Restore client confidence
  • Standardise fragmented global deployment processes
  • Reduce operational cost
  • Prepare the business for exit

Therefore the starting point was high risk.

The Situation

The company provides technology solutions supporting research and drug discovery. Operating across the UK, US, and Asia the business had been carved out and was preparing for private equity exit.

Nevertheless, the briefing with the client made the following issue clear:

  • Medical data services had a 98% failure rate
  • A key delivery team serving the top 20 global pharma clients was underperforming
  • Reporting timelines extended to 6 weeks
  • Processes were inconsistent across geographies
  • Morale was strained
  • Client confidence was deteriorating

So that the reputational and valuation risk was significant.

Immediate Leadership Impact

Reporting directly to the COO, our interim moved quickly to stabilise both performance and morale.

“He integrated seamlessly into the team and was able to provide much needed technical and personal leadership. The team responded exceptionally well to his collaborative style, resulting in a very quick improvement in performance.” COO

Accordingly, rather than impose change from above, he focused on alignment, clarity and accountability. He introduced structured governance, defined ownership, and established individual and team development plans to restore confidence internally before tackling systemic issues.

Diagnosing and Fixing the Core Failure

The most urgent issue was the catastrophic failure rate within medical data services.

So that the interim decided to lead a detailed root cause analysis across technology, workflow and resourcing.

The result:

  • Software failure rate reduced from ~90% to under 5%
  • Critical data integrity issues remediated
  • Significant reduction in rework
  • Restoration of client trust

The COO commented on the turnaround:

Our key delivery team, responsible for servicing the top 20 pharma, had been underperforming in terms of quality and delivery. The interim joined the team and was able to mobilise the team, improving morale and focussing on the key issues affecting performance.”

As a result, the improvement was measurable — and visible to clients.

Standardisation, Automation & Scalability

Beyond remediation, the interim ensured structural change, this meant:

  • Standardised global deployment processes across products and regions
  • Introduced automation in reporting workflows
  • Reduced reporting timelines from 6 weeks to under 1 week
  • Embedded improved software development lifecycle (SDLC) discipline and process governance

As a result, rigorously transforming people, process and technology created a repeatable, scalable deployment model — critical for a PE-backed business preparing for sale.

Immediate EBITDA Enhancement

During the transformation, he identified significant cloud cost inefficiencies and therefore led a cloud optimisation initiative that delivered:

  • $1 million in recurring annual savings
  • Improved cost transparency
  • Stronger margin profile ahead of exit

This output was a huge win because for private equity sponsors, recurring cost reduction directly supports valuation uplift.

The Result

Within just a few months the interim delivered the following results:

  • Operational stabilisation of a failing service line
  • Reduction in failure rates from crisis levels to <5%
  • Restored performance for top-tier pharma clients
  • $1M annualised cost savings
  • Standardised and automated global deployment model
  • Strengthened and empowered leadership team
  • Exit-ready operational framework

Therefore, the business could  then move from reactive crisis management to structured, predictable delivery.

 “Holdsway’s interim was able to make improvements by identifying and solving key resourcing gaps as well as strengthening workflows and processes to improve quality. Following these targeted interventions, we saw a very quick improvement on performance, backed up by positive feedback from key clients.” COO

Why PE Sponsors and CEOs Engage This Interim

He specialises in stepping into:

  • PE carve-outs under operational strain
  • Portfolio companies preparing for exit
  • Organisations facing delivery failure or reputational risk
  • Global teams requiring alignment and accountability
  • Situations demanding immediate EBITDA impact

He combines:

✔ Rapid operational diagnostics
✔ Hands-on execution
✔ Collaborative leadership that mobilises teams
✔ Technology and deployment expertise
✔ Measurable cost reduction
✔ Exit-readiness mindset

Introduced by Holdsway to deliver milestone-based transformation of people, process and technology, he demonstrated how interim leadership can quickly de-risk operations, rebuild confidence and materially enhance valuation.

Finally, what was the legacy of Holdsway’s interim?

Operational stabilisation.
Client confidence restored.
Cost reduction delivered.
Transformation embedded.

When performance matters — speed, credibility and execution define the outcome.

If your company is facing operational instability, delivery breakdown or exit pressure, interims from our fully interviewed, screened and benchmarked network are available for confidential discussion

Copyright 2026, Holdsway Limited. Registered in England & Wales No: 08640951